Purple Book product · Reference 351(a)
Elitek
rasburicase
Jan 06, 2006
Approved
Reference 351(a)
License type
Rx
Marketing
None
Listed patents
Sourced from the FDA Purple Book · verified Jul 02, 2026
Key dates
Approval
Approval date of this BLA submission.
Jan 06, 2006
20 yr 10 mo ago
Orphan exclusivity ends
7-year orphan-drug exclusivity window.
Jul 12, 2009
17 yr 3 mo ago
Today
Pharmaceutical detail
Strength
7.5MG
Dosage form
For Injection
Route
Intravenous
Presentation
Single-Dose Vial
Center
CDER
License number
1752
Product number
002
Submission type
Supplement
Supplement number
5020
Change type
Not listed
Reference product family
View full familyThis is the reference (originator) product. No biosimilars or interchangeables reference it in the Purple Book yet.
1 additional BLA record for this product (other strengths or presentations) are in the same reference family.
Patent list
No patent-list records were published for this product. The Purple Book patent list reflects the statutory patent exchange under the BPCIA and is not exhaustive.
Source provenance
- advanced-searchAdvanced Search · Jul 02, 2026
- monthly-downloadMonthly download · Jul 02, 2026
Change history
- v4Jul 02, 2026
- v3Jul 02, 2026
- v2Jul 02, 2026
Frequently asked questions
Does Elitek have approved biosimilars?
No 351(k) biosimilars or interchangeable biosimilars referencing Elitek are listed in the FDA Purple Book yet.
What is Elitek's BLA number?
Elitek is licensed under BLA 103946, held by Sanofi-Aventis U.S. LLC.
When was Elitek approved by the FDA?
Elitek was approved by the FDA on Jan 06, 2006.
Related FDA reference tools
- FDA Orange BookApproved drugs, generics, therapeutic-equivalence codes, patents, and exclusivity.
- FDA BiosimilarsThe list of FDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 & Inspection DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
